TISIDB

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Endosome. Endoplasmic reticulum. Note=Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane.; SUBCELLULAR LOCATION: Isoform 2: Secreted.; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm
Domain	PF07679 Immunoglobulin I-set domain PF07714 Protein tyrosine kinase
Function	Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.

> Gene Ontology [ TOP ]
Biological Process	GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0006661 phosphatidylinositol biosynthetic process GO:0006694 steroid biosynthetic process GO:0006699 bile acid biosynthetic process GO:0008202 steroid metabolic process GO:0008206 bile acid metabolic process GO:0008543 fibroblast growth factor receptor signaling pathway GO:0008654 phospholipid biosynthetic process GO:0010565 regulation of cellular ketone metabolic process GO:0010715 regulation of extracellular matrix disassembly GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0016053 organic acid biosynthetic process GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0019216 regulation of lipid metabolic process GO:0019218 regulation of steroid metabolic process GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0030258 lipid modification GO:0032844 regulation of homeostatic process GO:0033500 carbohydrate homeostasis GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process GO:0042180 cellular ketone metabolic process GO:0042593 glucose homeostasis GO:0042632 cholesterol homeostasis GO:0043062 extracellular structure organization GO:0043410 positive regulation of MAPK cascade GO:0044283 small molecule biosynthetic process GO:0044344 cellular response to fibroblast growth factor stimulus GO:0045017 glycerolipid biosynthetic process GO:0045862 positive regulation of proteolysis GO:0046394 carboxylic acid biosynthetic process GO:0046474 glycerophospholipid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046777 protein autophosphorylation GO:0046834 lipid phosphorylation GO:0046854 phosphatidylinositol phosphorylation GO:0046890 regulation of lipid biosynthetic process GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0050810 regulation of steroid biosynthetic process GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0055062 phosphate ion homeostasis GO:0055081 anion homeostasis GO:0055088 lipid homeostasis GO:0055092 sterol homeostasis GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0070857 regulation of bile acid biosynthetic process GO:0071774 response to fibroblast growth factor GO:0071897 DNA biosynthetic process GO:0072330 monocarboxylic acid biosynthetic process GO:0072506 trivalent inorganic anion homeostasis GO:1903053 regulation of extracellular matrix organization GO:1904251 regulation of bile acid metabolic process GO:2000188 regulation of cholesterol homeostasis GO:2000278 regulation of DNA biosynthetic process GO:2000573 positive regulation of DNA biosynthetic process
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005007 fibroblast growth factor-activated receptor activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0016303 1-phosphatidylinositol-3-kinase activity GO:0017134 fibroblast growth factor binding GO:0019199 transmembrane receptor protein kinase activity GO:0019838 growth factor binding GO:0035004 phosphatidylinositol 3-kinase activity GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0052742 phosphatidylinositol kinase activity GO:0052813 phosphatidylinositol bisphosphate kinase activity GO:1901681 sulfur compound binding
Cellular Component	GO:0030133 transport vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04144 Endocytosis hsa04151 PI3K-Akt signaling pathway hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-5654716: Downstream signaling of activated FGFR4 R-HSA-2871796: FCERI mediated MAPK activation R-HSA-190322: FGFR4 ligand binding and activation R-HSA-1839128: FGFR4 mutant receptor activation R-HSA-5654712: FRS-mediated FGFR4 signaling R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-180292: GAB1 signalosome R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-5654733: Negative regulation of FGFR4 signaling R-HSA-199418: Negative regulation of the PI3K/AKT network R-HSA-5654720: PI-3K cascade R-HSA-109704: PI3K Cascade R-HSA-2219528: PI3K/AKT Signaling in Cancer R-HSA-198203: PI3K/AKT activation R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling R-HSA-1257604: PIP3 activates AKT signaling R-HSA-5654228: Phospholipase C-mediated cascade; FGFR4 R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-5654719: SHC-mediated cascade R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-190236: Signaling by FGFR R-HSA-1226099: Signaling by FGFR in disease R-HSA-5654743: Signaling by FGFR4 R-HSA-5655291: Signaling by FGFR4 in disease R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation R-HSA-1307965: betaKlotho-mediated ligand binding

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04810 Regulation of actin cytoskeleton

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-5654716: Downstream signaling of activated FGFR4
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-190322: FGFR4 ligand binding and activation
R-HSA-1839128: FGFR4 mutant receptor activation
R-HSA-5654712: FRS-mediated FGFR4 signaling
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5654733: Negative regulation of FGFR4 signaling
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-5654720: PI-3K cascade
R-HSA-109704: PI3K Cascade
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-5654228: Phospholipase C-mediated cascade; FGFR4
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-5654719: SHC-mediated cascade
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654743: Signaling by FGFR4
R-HSA-5655291: Signaling by FGFR4 in disease
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-1307965: betaKlotho-mediated ligand binding

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FGFR4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FGFR4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FGFR4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.607	0.255
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.655	0.0674
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.15	0.857
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.326	0.549
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.22	0.884
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.013	0.57
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.409	0.0174
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.988	0.262
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.788	0.0589
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-1.016	0.547
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.486	0.523
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.222	0.299

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FGFR4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	0	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	0	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FGFR4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FGFR4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FGFR4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FGFR4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FGFR4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FGFR4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FGFR4
Name	fibroblast growth factor receptor 4
Aliases	JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location	5q35.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FGFR4 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting FGFR4.

ID	Name	Drug Type	Targets	#Targets
DB00039	Palifermin	Biotech	FGFR1, FGFR2, FGFR3, FGFR4, HSPG2, NRP1	6
DB01109	Heparin	Small Molecule	F10, FGF1, FGF19, FGF2, FGF4, FGFR1, FGFR2, FGFR4, HGF, PF4, SELP, ......	12
DB08901	Ponatinib	Small Molecule	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......	15
DB09078	Lenvatinib	Small Molecule	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, KIT	8

Browse FGFR4